Is cabozantinib effective in treating liver cancer?

Cabozantinib, also known as XL184, is an oral multi-target small molecule tyrosine kinase inhibitor. It has attracted widespread attention in the field of anti-cancer due to its unique multi-target inhibitory effect.

Cabozantinib can act on up to 9 targets, including RET, MET, ROS1, VEGFR1/2/3, AXL, NTRK, KIT, etc. This multi-target feature makes cabozantinib a promising candidate for anti-cancer treatment. Especially in the treatment of liver cancer, these targets are closely related to the occurrence and development of liver cancer, so cabozantinib can slow down the growth and spread of tumors by inhibiting the activity of these targets.

In a large international multi-center phase III clinical trial, cabozantinib, as a second-line treatment drug, significantly prolonged the survival of patients with liver cancer. Specifically, the median survival with cabozantinib was 10.2 months, and progression-free survival (PFS) was 5.2 months. In comparison, survival in the placebo group was only 8 months and progression-free survival was only 1.9 months. This data fully demonstrates the significant effect of cabozantinib in prolonging the survival of patients with liver cancer.

According to clinical trial results, the risk of death in patients with advanced liver cancer who received cabozantinib was reduced by 37%. This data further confirms the effectiveness of cabozantinib in the treatment of liver cancer.

Although the objective effective rate of cabozantinib treatment is approximately 5%, considering the refractory and complex nature of liver cancer, this effective rate still has certain clinical significance. Cabozantinib may be an effective treatment option, particularly for patients who do not respond well to conventional treatments.

Cabozantinib can also be used in combination with other drugs such as regorafenib, PD-1 antibodies, etc., and has become one of the second-line treatment options for advanced liver cancer in European and American countries. This combined treatment regimen is expected to further improve the survival and quality of life of liver cancer patients.

Cabozantinib was relatively well tolerated by patients, according to clinical trial data. Although some side effects may occur during use, such as hypertension, mucositis, or gastrointestinal discomfort, most patients are able to tolerate these side effects and complete the treatment cycle.

Although cabozantinib has shown significant efficacy in the treatment of liver cancer, patients may also experience some side effects during use. Common side effects include fatigue, diarrhea, nausea, etc. However, these side effects can usually be alleviated with appropriate medication modification and supportive care. Doctors will develop appropriate treatment plans based on the patient's specific conditions to minimize the impact of side effects on the patient.

In addition, cabozantinib not only shows potential in the treatment of liver cancer, but also shows good therapeutic effects in a variety of other solid tumors such as kidney cancer, thyroid cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer and intestinal cancer. This further demonstrates the broad application prospects of cabozantinib as a broad-spectrum anticancer drug.